VeenemaR. J., DeanA. L.jr., RobertsM., FingerhurtB., ChowdhuryB. K., TarassolyH.: Bladder carcinoma treated by direct instillation of thiotepa. J. Urol., 88; 60–63 (1962).
2.
BurnandK. G., BoydP. J. R., MayoM. E., ShuttleworthK. E. D., Lioyd DaviesR. W.: Single-dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Brit. J. Urol., 48; 55–59 (1976).
3.
KoontzW. W.jr., ProutG. R.jr., SmithW., FrableW. J., MinnisJ. E.: Use of intravesical thio-tepa in management of non-invasive carcinoma of bladder. J. Urol., 125; 307–312 (1981).
4.
ByarD., BlackardC., Veterans Administration Cooperative Urological Research Group: Comparisons of placebo, pyridoxine, and topical thio-tepa in preventing recurrence of stage I bladder cancer. Urology, 10; 556–561 (1977).
5.
ShulmanC., SylvesterR., RobinsonM., SmithP., LachandA., DenisL., Pavone-MacalusoM., De PauwM., StaquetM.: Adjuvant therapy of T1 bladder carcinoma: preliminary results of an EORTC randomized study. Recent Results Cancer Res., 68; 338–345 (1979).
6.
Pavone-MacalusoM., CaramiaG., RizzoF. P.: The use of chemotherapeutic agents in the prophylaxis of papillary bladder tumours. Urol. Intern., 26; 379–387 (1971).
7.
ColleenS., EkA., HellstenS., LindholmC. E.: Intracavitary epodyl for multiple, non invasive, highly differentiated bladder tumours. Scand. J. Urol. & Nephrol., 14; 43–45 (1980).
8.
NielsenH. V., ThyboE.: Epodyl treatment of bladder tumours. Scand. J. Urol. & Nephrol., 13; 59–63 (1979).
9.
RobinsonM. R. G., ShettyM. B., RichardB., BastableJ., GlashanR. W., SmithP. H.: Intravesical epodyl in the management of bladder tumors: combined experience of the Yorkshire Urological Cancer Research Group. J. Urol., 118; 972–973 (1977).
10.
BussaniF., ProperziA., PattitiA., BoscoA.: L'impiego della doxorubicina nella chemioprofilassi topica dei tumori superficiali della vescica. Urologia, 49; 619–623 (1982).
11.
MinocciD., MartinengoC., PrettiG.: Chemioprofilassi con doxorubicina dei tumori superficiali della vescica: nostra esperienza. Atti XXXII Conv. Soc. Urologi Nord Italia (in corso di stampa).
12.
JakseG., HofstädterF., MarbergerH.: Intracavitary doxorubicin hydrochloride therapy for carcinoma in situ of the bladder. J. Urol., 12; 185–190 (1981).
13.
NeedlesB., BlumenereichM., YagodaA., SoganiP., WhitmoreW. F.: Intravesical cisplatinum for superficial bladder cancer. Proc. Amer. Assoc. Cancer Res., 22; 158 e 625 (1981).
14.
MishinaT., OdaK., MurataS., OoeH., MoriY., TakahashiT.: Mitomycin C bladder instillation therapy for bladder tumors. J. Urol., 114; 217–219 (1975).
15.
SolowayM. S., MurphyW. M., DefuriaM. D.: Intravesical Mitomycin C in superficial bladder cancer. Proc. Amer. Soc. Clin. Oncol., 22; 469 (1981).
16.
SolowayM. S., MurphyW. M., DefuriaM. D., CrookeS. T., Fine BaumP.: The effect of Mitomycin C (MMC) on superficial bladder cancer. J. Urol., 125; 646–648 (1981).
17.
PansadoroV., DefidioL., BenincasaA., RoselliD., Pulone.: La Mitomicina C nel trattamento topico dei tumori vescicali. Atti LIV Congr. S.I.U., Bologna1981, vol. II, p. 821–826.
